Cardlytics reported a challenging fourth quarter with a 24.2% revenue decline, primarily driven by the conclusion of major bank campaigns. Despite the revenue drop, the company improved its bottom line, achieving positive Adjusted EBITDA and positive Free Cash Flow through disciplined cost management and a reduction in net loss.

Cardlytics announced its Q3 2025 financial results, with revenue decreasing by 22% year-over-year to $52.0 million and billings decreasing by 20% to $89.2 million. Despite the revenue decline, the company significantly reduced its net loss to $(72.7) million from $(145.2) million in the prior year, and achieved a positive Adjusted EBITDA of $3.2 million compared to a negative $(1.8) million in Q3 2024. Monthly Qualified Users (MQUs) increased by 21% to 230.3 million.

Cardlytics reported a revenue of $63.2 million for Q2 2025, a 9% decrease year-over-year. The company's net loss widened to $(9.3) million, or $(0.18) per diluted share, from $(4.3) million in Q2 2024. Despite the revenue decline, Adjusted EBITDA turned positive at $2.7 million, up from $(2.3) million in the prior year.

Cardlytics reported a decrease in revenue and billings for the first quarter of 2025 compared to the same period in the previous year. While net loss improved, Adjusted EBITDA and Adjusted Net Loss worsened. The company saw an increase in monthly qualified users but a decrease in adjusted contribution per user.

Cardlytics' Q4 2024 revenue was $74.0 million, a 17.0% decline year-over-year, mainly due to lower advertising demand. The company reported a net loss of $15.6 million but improved adjusted EBITDA to $6.4 million. MAUs decreased slightly, while ARPU dropped 16.7% year-over-year.

Cardlytics reported a revenue of $67.1 million, a 15% decrease year-over-year, and a net loss of $145.2 million, or $2.90 per diluted share, compared to a net loss of $24.0 million, or $0.63 per diluted share in the third quarter of 2023. The company's MAUs increased by 2% year-over-year to 166.4 million, while ARPU decreased to $0.40 from $0.49 in the third quarter of 2023.

Cardlytics reported a revenue of $69.6 million, a decrease of 9% year-over-year. The company's MAUs increased by 3% year-over-year, reaching 165.5 million, while ARPU decreased to $0.42. The company is focused on modernizing its platform and confident in long term growth.

Cardlytics reported a 5% year-over-year increase in revenue, reaching $67.6 million, and a 10% increase in billings to $105.2 million. The company experienced a net loss of $(24.3) million, but achieved positive Adjusted EBITDA of $0.2 million. MAUs increased by 7% year-over-year to 168.5 million.

Cardlytics reported an 8.1% increase in total revenue to $89.2 million for Q4 2023, compared to $82.5 million in Q4 2022. The company's net loss attributable to common stockholders was $(100.8) million, or $(2.56) per diluted share, compared to a net loss of $(378.3) million, or $(11.32) per diluted share in Q4 2022. Adjusted EBITDA was $10.0 million, a $16.1 million increase compared to $(6.1) million in Q4 2022.

Cardlytics reported a 9% year-over-year increase in revenue, reaching $79.0 million for the third quarter of 2023. The company also saw a significant improvement in gross profit, which increased by 38% compared to the same period last year. Additionally, Cardlytics reported a net loss attributable to common stockholders of $(24.0) million, or $(0.63) per diluted share, and a non-GAAP net loss was $0.3 million, or $0.01 per diluted share.

Cardlytics reported a 2% year-over-year increase in revenue, reaching $76.7 million. The company's net loss attributable to common stockholders significantly improved to $(23.5) million, compared to $(126.3) million in the second quarter of 2022. Key metrics such as MAUs also saw growth, while ARPU remained consistent year-over-year.

Cardlytics' Q1 2023 revenue was $64.3 million, a decrease of 5% year-over-year. Net income attributable to common stockholders was $13.6 million, or $0.40 per diluted share. Cardlytics MAUs were 188.8 million, an increase of 6% year-over-year.

Cardlytics reported a decrease in total revenue for Q4 2022, with a net loss attributable to common stockholders. However, the company saw an increase in MAUs and Bridg ARR.

Cardlytics announced its Q3 2022 financial results, demonstrating a 12% year-over-year revenue increase to $72.7 million. The company reported a net income attributable to common stockholders of $6.3 million, or $0.19 per diluted share, compared to a net loss of $(44.5) million, or $(1.35) per diluted share in Q3 2021.

Cardlytics announced financial results for the second quarter ended June 30, 2022, revealing a 28% increase in revenue year-over-year to $75.4 million. However, the net loss attributable to common stockholders significantly increased to $(126.3) million, or $(3.75) per diluted share, compared to $(47.3) million, or $(1.43) per diluted share, in the second quarter of 2021.

Cardlytics reported a strong Q1 2022 with revenue of $67.9 million, a 28% increase year-over-year. The company achieved net income attributable to common stockholders of $33.0 million, or $0.91 per diluted share, compared to a net loss of $(24.9) million, or $(0.85) per diluted share in the first quarter of 2021.

Cardlytics' Q4 2021 financial results showed a 34.2% increase in total revenue to $90.0 million compared to Q4 2020. The company reported a net loss of $(11.8) million, or $(0.35) per diluted share. Billings increased by 42.6% to $134.0 million, and adjusted contribution rose by 48.5% to $44.0 million.

Cardlytics reported a solid third quarter in 2021 with revenue of $65.0 million, a 41% increase year-over-year, and billings of $98.4 million, a 59% increase year-over-year. The company's key metrics, including MAUs and ARPU, also saw growth, and Bridg ARR reached $12.7 million.

Cardlytics announced its Q2 2021 financial results, with revenue increasing by 109% year-over-year to $58.9 million and billings increasing by 116% to $85.3 million. However, the company reported a net loss attributable to common stockholders of $(47.3) million, or $(1.43) per diluted share.

Cardlytics announced a 17% year-over-year increase in revenue, reaching $53.2 million for Q1 2021. The company's performance reflects a continued positive trajectory, further enhanced by the Dosh acquisition and the anticipated benefits from the upcoming Bridg acquisition.

Cardlytics announced its Q4 2020 financial results, with total revenue decreasing by 3.2% to $67.1 million compared to Q4 2019. The company reported a net loss attributable to common stockholders of $(6.8) million, or $(0.24) per diluted share, and a non-GAAP net loss of $(1.5) million, or $(0.05) per diluted share. Average FI MAUs increased by 22.6% to 163.6 million, while ARPU decreased by 21.2% to $0.41.

Cardlytics reported a decrease in revenue and billings compared to the third quarter of 2019. Revenue was $46.1 million, an 18% decrease year-over-year, while billings decreased by 25% to $62.1 million. The company's net loss was $(15.2) million, or $(0.56) per diluted share.

Cardlytics reported a revenue of $28.2 million, a 42% decrease year-over-year. The company's FI MAUs increased by 31% to 157.2 million, but ARPU decreased by 55% to $0.18. The company is optimistic about long-term growth due to the launch of Wells Fargo and progress in product development initiatives.

Cardlytics announced financial results for the first quarter ended March 31, 2020. Revenue was $45.5 million, an increase of 26% year-over-year. FI MAUs were 140.8 million, an increase of 30%, and ARPU was $0.32, a decrease of (3)%.

Cardlytics announced strong Q4 2019 financial results, with total revenue increasing by 44.9% year-over-year to $69.3 million. The company reported net income attributable to common stockholders of $3.4 million, or $0.12 per diluted share, and non-GAAP net income of $5.2 million, or $0.18 per diluted share. Average FI MAUs increased by 60.3% to 133.4 million, while ARPU decreased by 8.8% to $0.52.